Evaluation of tulathromycin in the treatment of pulmonary abscesses in foals

Tulathromycin is a new injectable macrolide antibiotic used for the treatment of pulmonary diseases of swine and cattle. In this study, 37 foals with sonographic evidence of lung abscesses were treated with tulathromycin (2.5 mg/kg intramuscularly [IM] once weekly, group 1) and 33 foals (group 2) wi...

Full description

Saved in:

Bibliographic Details
Published in:	The veterinary journal (1997) Vol. 174; no. 2; pp. 418 - 421
Main Authors:	Venner, Monica, Kerth, Regina, Klug, Erich
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-09-2007
Subjects:	abscess Administration, Oral Animals Animals, Newborn Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Antibiotic Azithromycin - administration & dosage Azithromycin - therapeutic use Disaccharides - administration & dosage Disaccharides - adverse effects Disaccharides - therapeutic use drug evaluation drug therapy Drug Therapy, Combination Foals Heterocyclic Compounds - administration & dosage Heterocyclic Compounds - adverse effects Heterocyclic Compounds - therapeutic use horse diseases Horse Diseases - drug therapy Horses Injections, Intramuscular - veterinary intramuscular injection Lung Abscess - drug therapy Lung Abscess - veterinary Lung abscesses lungs macrolide antibiotics Random Allocation Rifampin - therapeutic use Time Factors Treatment Treatment Outcome Tulathromycin veterinary drugs Foals Antibiotic Treatment Tulathromycin Lung abscesses
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Tulathromycin is a new injectable macrolide antibiotic used for the treatment of pulmonary diseases of swine and cattle. In this study, 37 foals with sonographic evidence of lung abscesses were treated with tulathromycin (2.5 mg/kg intramuscularly [IM] once weekly, group 1) and 33 foals (group 2) with a combination of azithromycin (10 mg/kg per os [PO] once daily for the first seven days of therapy, thereafter every other day) and rifampin (10 mg/kg PO twice daily). The bacterial aetiological agent was not determined. The foals were only mildly sick and the median number of pulmonary abscesses was 1.4 (group 1) and 1.6 (group 2). Thirty foals in each group were treated without modifying therapy protocols until all clinical signs of disease had subsided. Tulathromycin was administered for a mean of 53 days, and azithromycin/rifampin for 42 days. The following side effects were associated with tulathromycin (279 IM injections): self-limiting diarrhoea in 11 foals; elevated temperature in six foals, and swellings at the injection site in 12 foals. This study provides some evidence that tulathromycin is well tolerated and appears promising for the treatment of pulmonary abscesses in foals.
Bibliography:	http://dx.doi.org/10.1016/j.tvjl.2006.08.016
ISSN:	1090-0233 1532-2971
DOI:	10.1016/j.tvjl.2006.08.016